INTRODUCTION {#sec1-1}
============

Ewing's sarcoma is a malignant bone tumor, accounting for approximately 10% of primary bone malignancies \[[@ref33]\] and usually occurring in the first or second decade of life \[[@ref13]\] with no sex predilection. \[[@ref1]\] Metastases of Ewing's sarcoma to the central nervous system (CNS) are uncommon \[[@ref19]\] and metastases that originate from the dura are exceedingly rare.

To the best of our knowledge, only two cases have been published in the English medical literature. \[[@ref19][@ref21]\] We present an additional case of metastatic dural Ewing's sarcoma mimicking a parasagittal meningioma, in a 24-year old female and discuss the pathogenesis of these unusual tumors with review the relevant literature concerning their treatment and outcome.

CASE REPORT {#sec1-2}
===========

A 24-year-old right-handed female was admitted to our hospital complaining of a 2-week history of moderate headache and weakness in her left leg for the past 2 days. She did not present with nausea, vomiting, dizziness, or seizures but reported an underestimated weight loss in the last 3 months.

Her medical history was significant for a Pelvis Ewing's sarcoma, operated with complete surgical removal and stabilization one and a half year ago \[[Figure 1](#F1){ref-type="fig"}\], and was recently diagnosed as having small lung metastases.

![Pelvis X-rays showing left iliac wing reconstruction with tibial autografts and stabilization with screw-rod type osteosynthesis](SNI-4-96-g001){#F1}

On admission, the patient's neurological examination revealed no cognitive deficits but a left sided leg monoparesis with motor strength of 3/5. The deep tendon reflexes in her left leg were hyperreactive and the gait and standing position were impossible. Fundoscopic examination showed a grade II papilledema. The physical examination disclosed neither local signs of relapse at the primary site nor other clinical signs of metastatic spread.

The computed tomography (CT) scan showed an extra-axial, dural based, heterogeneously hyperdense, and enhancing lesion in the right frontoparietal parasagittal region, with moderate circumferential edema and mass effect \[[Figure 2](#F2){ref-type="fig"}\]. No abnormalities in the skull abutting to the tumor were noted \[[Figure 3](#F3){ref-type="fig"}\] and imaging features were strongly suggestive of a meningioma.

![Preoperative plain CT scan (a) and postcontrast CT scan images (b), (c) and (d) showing a rounded, well-defined, heterogeneously hyperdense, and enhancing lesion in the right frontoparietal region, with circumferential edema and mass effect](SNI-4-96-g002){#F2}

![Bone window CT scan in sagittal view obtained at the time of admission showing no osteolytic changes of the calvarial bone](SNI-4-96-g003){#F3}

Magnetic resonance imaging (MRI) delineated better the tumor with its marked surrounding edema. The tumor appeared hypointense on T1-weighted MRI scans, hyperintense on T2-weighted MRI scans and displayed important enhancement with gadolinium. The tumor was attached to the dura of the convexity with present dural tail sign and invaded partially the superior sagittal sinus increasing evidence of a meningeal tumor \[[Figure 4](#F4){ref-type="fig"}\].

![Preoperative axial (a) and coronal (b) postgadolinium T1-weighted MRI images, showing a strongly enhancing right frontoparietal tumor with sagittal venous sinus invasion. Note the dural tail indicating a meningeal tumor](SNI-4-96-g004){#F4}

The patient underwent a right frontoparietal craniotomy with an amazing discovery: The tumor was associated with a small lobulated epidural extension tightly attached to the skull \[[Figure 5](#F5){ref-type="fig"}\]. Macroscopic examination showed a reddish gray, rubbery in consistency and vascular tumor of dural origin. The tumor invaded the superior sagittal sinus but has clear delineation with cerebral parenchyma allowing near total excision; only a small portion involving the superior sagittal sinus was left and the remaining dural edges were coagulated.

![Intraoperative photograph of the bone flap showing extradural lobulated tumor tissue tightly attached to the inner calvarial bone](SNI-4-96-g005){#F5}

The definitive histological diagnosis was metastatic Ewing's sarcoma. The tumor was composed of densely packed, small round, dark staining cells with scanty cytoplasm on light microscopy \[[Figure 6](#F6){ref-type="fig"}\]. A strong MIC-2 antigen expression was noted on immunohistochemical study.

![Hematoxylin and eosin-stained tumor specimen showing densely packed, small round cells with scanty clear cytoplasm and regular vesicular and hyper chromatic nuclei; magnification, ×200](SNI-4-96-g006){#F6}

The patient's immediate postoperative course was uneventful, and she recovered quickly. Her neurological condition improved continuously, and follow-up examinations showed that the monoparesis had disappeared completely. A postoperative CT scan confirmed the extent of tumor resection with a postoperative craniotomy defect \[[Figure 7](#F7){ref-type="fig"}\].

![Postoperative coronal CT scan showing near total tumor removal with craniotomy defect](SNI-4-96-g007){#F7}

The patient was administered a 55 Gy radiation therapy along with an adjunctive high dose chemotherapy associating alkylating agents and doxorubicin. Clinical status remained unchanged till the most recent follow-up examination, 8 months after surgery.

DISCUSSION {#sec1-3}
==========

Ewing's sarcoma accounts for 10% of primary bone malignancies and usually occurs in the first or second decade of life \[[@ref13]\] with no sex predilection. \[[@ref1]\]

It was first described by James Ewing in 1921, who attributed its origin to bone endothelial cells \[[@ref10]\] but now is considered as a part of Ewing's sarcoma family of tumors (ESFTs), which is a classification used to describe a heterogeneous group of small round blue cell neoplasms of neuroectodermal origin. \[[@ref2][@ref15][@ref19]\]

This malignant tumor often presents as a solitary mass affecting mainly long bones and the pelvic girdle \[[@ref5][@ref12][@ref25][@ref28]\] with a high propensity to metastasize to the lungs (38%), bone (31%), and bone marrow (11%). \[[@ref19][@ref30]\]

Ewing's sarcoma can also metastasize to the CNS with a relatively low incidence (6.3% of cases). \[[@ref38]\] There are two reported principal modes of metastatic spread of Ewing's sarcoma to the CNS. The first is direct extension from the skull, which may be the site of both primary and secondary Ewing's sarcoma. \[[@ref24]\] Alternatively, it may reach the CNS via hematogenous spread. \[[@ref19]\]

The main question raised in this case is: What is the true origin of such tumor? Is it bone or dura?

The pathogenesis includes two conceivable possibilities for meningeal involvement in this type of tumor presentation: (1) dural metastasis of the pelvic Ewing's sarcoma; (2) direct extension of a skull metastasis with dural breakthrough and massive intradural extension.

What is already known is that, when located within the skull (less than 1% of cases), \[[@ref4][@ref8][@ref14]\] these tumors tend to pass the cortical of the bone of origin to spread into the adjacent soft tissues \[[@ref33]\] but in such reported presentations, dural break through was associated with diffuse massive epidural masses \[[@ref17][@ref21]\] responsible of what so called volcano-shape radiological feature. \[[@ref17]\]

In contrast, dural metastasis may mimic skull metastasis. \[[@ref16]\]

This and regard of our patient's tumor presentation, make us believe that the tumor really originates from the dura in the present case. And that Ewing's sarcoma should be considered in the differential diagnosis of extra-axial dural masses particularly meningiomas.

Dural metastases accounts for 9% of all CNS metastases. However, dural metastasis of Ewing's sarcoma has rarely been reported on. To the best of our knowledge, only two cases have been published in the English medical literature. \[[@ref19][@ref21]\] Kleinschmidt-DeMasters \[[@ref21]\] was the first to describe a dural metastasis of Ewing's sarcoma in his 2001 surgical and autopsy series but dural involvement was associated with a massive epidural plaque-like nodule. Such a finding and the lack of imaging investigations makes it difficult to determine the true origin of the dural lesion in that case. Kim *et al.* \[[@ref19]\] in their 2008 radiology report, presented the second published case. In that report, the lesion was a purely intracranial dural mass, which was considered as a metastatic tumor because of a subsequent recurrence uncommon with primary Ewing's sarcoma. What makes our case unique is that not only it was associated with a small epidural involvement not visible in radiological examinations but also evidence of metastatic spread is already established.

Metastases are present in about 25% of Ewing's sarcoma cases at diagnosis \[[@ref9]\] and in 75-80% within the first 2 years of evolution \[[@ref8]\] and in the natural history of sarcoma it is reported that the time between diagnosis and brain metastasis is usually between 3 months and 1 year \[[@ref34]\] Such metastases most often follow lung metastasis (57-80% of patients), which is verified in the present case.

Generally the tumor presents with features of raised intracranial pressure as well as focal neurological deficits \[[@ref4][@ref8][@ref14][@ref26]\] and the imaging characteristics of this rare tumor in an extra-axial location consists of high attenuation on CT, which can show the intracranial or extra cranial extension of the tumor as well as even slight bone destruction. \[[@ref24][@ref37]\] MRI will show low signal intensity on T2-weighted sequences, \[[@ref24]\] which usually suggest hyper cellularity, well known in this category of tumors and by providing multiplanar views it will also demonstrate the tumor extent, which is of great help in surgical planning. \[[@ref39]\] Actually, positron emission tomography-CT is increasingly used in the staging of cancers, but has not been found as sensitive as MRI in the evaluation of brain metastases. \[[@ref11]\] Imaging features of our patient's tumor were more suggestive of a meningioma than a metastatic Ewing's sarcoma.

The diagnosis of CNS Ewing's sarcoma is based on histological and immunohistochemical analysis and apart from conventional assessment, staining for neural markers (NSE, Neurofilaments, S-100 and synaptophysin) should be performed. \[[@ref2]\] Histological features of our patient's tumor were typical of Ewing's sarcoma.

The differential diagnosis of intracranial small round cell tumors apart of Ewing's sarcoma eloquently discussed by Navas-Palacinos *et al.* \[[@ref27]\] includes nonHodgkin lymphoma, metastatic neuroblastoma, and rhabdomyosarcoma. \[[@ref6][@ref8]\] In the present case, our initial differential diagnosis included more common tumors such as meningioma though age or medical history of the patient was not in favor. In fact, the combination of its infrequent location in the intradural compartment, along with the lack of distinctive imaging characteristics, compounds to the diagnostic pitfalls encountered with Ewing's sarcoma in such locations.

The optimal management of metastatic Ewing's sarcoma is still a challenge. Improved understanding of the biology of this tumor, as well as early detection and better multimodalities therapy has significantly improved survival for patients with Ewing's sarcoma affecting the CNS and literature suggests that timely radical resection followed by chemo radiation is of paramount importance to accomplish a favorable outcome. \[[@ref33][@ref35]\] Unfortunately, presurgical chemotherapy to downstage the tumor, as for extra cranial Ewing's sarcoma, may not be possible in this situation, as the majority of patients presents with rapidly increasing lesions with raised intracranial pressure. \[[@ref33]\] Furthermore, in metastatic disease, chemotherapy after intensive local treatment achieves disease-free survival rates lower than 10-20% at 5 years, \[[@ref3][@ref7][@ref9][@ref20][@ref40]\] rates that have not well improved by increasing the dose or with adjunction of alkylating agents or doxorubicin. \[[@ref16][@ref22][@ref29]\] Recently, several nonrandomized trials have assessed the value of more intensive, time-compressed or high dose chemotherapy approaches, followed by autologous stem cell rescue in advanced cases like ours, with promising results, but evidence of benefit, resulting from trials, is pending. \[[@ref23]\]

Ewing's sarcoma is a radiation sensitive tumor \[[@ref41]\] and it is necessary to administer full dose radiation therapy after an incomplete surgical resection. \[[@ref43]\] but toxicities of radiation combined with aggressive chemotherapy still requires further definition. To that aim, proton radiation therapy is actually conducted, offering nearly the same results with improved dose localization and safety for normal tissue \[[@ref32]\] but its availability is lacking.

There has been a wealth of recent advances in understanding the biology of Ewing's sarcoma and the unique biological factors responsible for tumor genesis are currently the target of trials to develop highly selective, safe, and efficacious therapies. Nowadays, molecular and biologically directed therapies are the attractive and emerging treatment modalities of Ewing's sarcoma as targeting the autocrine signaling pathways, including the insulin-like growth factor has been shown to decrease proliferation and increase apoptosis. \[[@ref18][@ref31][@ref36]\] But its use according to van de Luijtgaarden *et al.*, \[[@ref42]\] could be more effective in first line than in refractory or recurrent diseases, like ours, which are the ones in need of new therapeutic options.

CONCLUSION {#sec1-4}
==========

Metastatic Ewing's sarcoma to the CNS is a rare and challenging condition requiring a multidisciplinary team approach.

The case reported in this paper appears to represent a genuine example of occurrence of metastatic Ewing's sarcoma in the dura and that it should be included in the differential diagnosis of extra-axial dural masses particularly meningiomas.

We believe that in the era of personalized cancer therapy, strategies to develop drugs for uncommon tumors such as Ewing's sarcoma and to individualize therapy will be crucial.
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